ProCE Banner Activity

Fulvestrant ± Palbociclib in ER+/HER2- Breast Cancer: An Extended Follow-up of PALOMA-3

Slideset Download
Conference Coverage
Longer follow-up demonstrated that the addition of palbociclib to fulvestrant maintained a significant PFS improvement in patients with MBC.

Released: December 14, 2015

Expiration: December 12, 2016

No longer available for credit.

Share

Provided by

Jointly provided by Postgraduate Institute for Medicine and Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

Genentech BioOncology

Novartis Pharmaceuticals Corporation